Ocugen

Ocugen

Biotechnology
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

$345.9M

Market Cap • 9/25/2026

2000

(26 years)

Founded

2014

(12 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

—

P/S

75,5

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

—

EPS

—

Market Cap

Market Cap

345,9M

EV

333,8M

EV/Revenue

72,9

EV/EBITDA

-5

EV/EBIT

-4,8

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-16,8%

Total Yield

-16,8%

Payout

0%

Retained Earnings

-452,1M

Profitability

Gross Margin

100%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

955,5%

Capex/Revenue

3,3%

Capex/D&A

8,8%

Capex/OCF

-0,3%

SBC/OCF

—

% PPE

10,7%

% Goodwill

0%

ROE

1211,7%

ROIC

—

Growth

CAGR Op. Income 5Y

8,1%

CAGR Net Income 5Y

11,6%

CAGR OCF 5Y

12,3%

Leverage

N.D./EBITDA

0,2

Debt/Equity

0%

Current Ratio

0,8

Quick Ratio

0,8

Interest Coverage

816,2%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium